EXEL - Exelixis, Inc. Debt to Book Capitalization Ratio

Effective management at Exelixis, Inc. (EXEL) ensures high profitability by protecting Cabometyx patents. The current leverage ratio on balance sheet capital demonstrates financial stability, with the level sitting around 0.08. However, the development of targeted therapy requires colossal expenditures and strict government oversight. Business stability is supported by diversified raw material supply chains between Europe and the US.

EXEL Exelixis, Inc.: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for Exelixis Inc (EXEL)

- price and consensus price forecast:

Stock Price Exelixis, Inc.|EXEL - Consensus Target

- market capitalization data:

Market Value Exelixis Inc.|EXEL - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Exelixis|EXEL - Company Book Value|Market Value to Book Value Ratio exelixis.com|EXEL - Company Assets

- debt and liquidity data:

Total Debt to Capital Exelixis, Inc.|EXEL - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Exelixis Corp|EXEL - Company Cumulative Debt|Debt to Book Value Exelixis Inc.

Analysis of all company metrics:EXEL, Exelixis, Inc.

Fundamental selection of high-quality assets is based on solvency analysis via the total liabilities-to-equity ratio. This coefficient measures the business's reliance on borrowed funds, which is critical for Exelixis, Inc. (EXEL) when scaling therapy within the growing oncology segment; therefore, the current debt level relative to balance sheet equity serves as an indicator of financial resilience to market shocks.

Competitors of Exelixis, Inc. (EXEL)